Immunological Mechanisms in Type 1 Diabetes

Type 1 diabetes is characterised by immune-mediated destruction of pancreatic β cells, leading to absolute insulin deficiency. Central to disease initiation is a breakdown of self-tolerance in which genetic predisposition—especially HLA class II alleles—interacts with environmental triggers such as viral infection. Autoreactive CD8+ cytotoxic T lymphocytes recognise β-cell peptides presented by hyperexpressed HLA class I molecules, while CD4+ T helper cells amplify the response through pro-inflammatory cytokines. Beta cells themselves contribute to their demise by upregulating stress pathways, producing chemokines and neoantigens that further recruit immune effectors. B cell responses generate autoantibodies against insulin, GAD65 and other β-cell antigens, serving both as biomarkers and amplifiers of autoimmunity. Innate immune signals, including toll-like receptor activation by viral components, can precipitate a local inflammatory milieu and bystander activation of autoreactive clones. Regulatory T cells, which normally constrain autoimmunity, show quantitative or qualitative defects in patients, compromising peripheral tolerance. Recent advances reveal that interplay between endoplasmic reticulum stress, antigen processing machinery and the cytokine milieu determines β-cell vulnerability. Together, these mechanisms converge to drive progressive β-cell loss and onset of insulin dependence. A deeper understanding of the dialogue between pancreatic islets and the immune system is guiding development of antiviral strategies, immunomodulatory therapies and approaches to preserve or restore β-cell mass.

Research from Nature Portfolio

Recent clinical work has evaluated antiviral therapy in new-onset type 1 diabetes, targeting persistent enteroviral infection in pancreatic islets. In a double-blind, placebo-controlled trial, children and adolescents received a combination of pleconaril and ribavirin for six months. Treated participants exhibited significantly higher stimulated C-peptide levels at one year, indicating preserved endogenous insulin production, and the regimen was well tolerated. These findings provide proof of concept that targeted antiviral intervention can modulate the immunopathogenic cascade and delay β-cell decline in early disease.

Immunological Mechanisms in Type 1 Diabetes publication trend

The graph below shows the total number of articles in immunological mechanisms in type 1 diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

β cells: Insulin-secreting cells in the pancreatic islets responsible for glucose regulation.

C-peptide: Peptide fragment released in equimolar amounts with insulin, used as a measure of endogenous insulin secretion.

HLA class I antigens: Cell-surface proteins that present endogenous peptides to CD8+ T lymphocytes.

Cytotoxic T lymphocyte (CTL): CD8+ T cell subset that kills target cells displaying specific peptide–HLA class I complexes.

Molecular mimicry: Mechanism whereby similarity between foreign and self-peptides triggers autoreactive immune responses.

Autoantigen: Self-derived molecule targeted by the immune system in autoimmune disease.

References

1. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nature Medicine (2023).
2. Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial. Signal Transduction and Targeted Therapy (2023).
3. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia (2016).
4. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses (2019).